menu
    • menu
    [{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ 5AM Ventures"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Biotherapeutics \/ Merck"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"CD16","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AB-101","moa":"ADCC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Affimed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"AB-101","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Artiva Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Artiva Biotherapeutics \/ Jefferies"}]

    Find Clinical Drug Pipeline Developments & Deals by Artiva Biotherapeutics

    Menu

    Artiva Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $167.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq

                            Details : The net proceeds will be used to fund the clinical development of the company's lead product AlloNK (AB-101), which is being evaluated for the treatment of r/r Hodgkin Lymphoma.

                            Brand Name : AlloNK

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $167.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab,Cyclophosphamide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis

                            Details : AlloNK (AB-101) is an allogeneic NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity in combination with rituximab or obinutuzumab for treating lupus nephritis.

                            Brand Name : AlloNK

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : AB-101,Rituximab,Cyclophosphamide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with ...

                            Details : AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.

                            Brand Name : AlloNK

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 16, 2023

                            Lead Product(s) : AB-101,Rituximab

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFM13,AB-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Affimed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therap...

                            Details : AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.

                            Brand Name : AFM13

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2023

                            Lead Product(s) : AFM13,AB-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Affimed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFM13,AB-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Affimed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager ...

                            Details : Under the terms of the agreement, Affimed and Artiva will pursue the development of the AFM13/AB-101 combination treatment in the United States on a co-exclusive basis. Affimed will lead regulatory activities through Phase 2 and any confirmatory studies.

                            Brand Name : AFM13

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 03, 2022

                            Lead Product(s) : AFM13,AB-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Affimed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 ...

                            Details : AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-...

                            Brand Name : AB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of ...

                            Details : AB-201 is an allogeneic HER2-targeted CAR-NK cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model ...

                            Brand Name : AB-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Venrock Healthcare Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

                            Details : Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy which is currently under Phase 1/2 clinical trial in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.

                            Brand Name : AB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Venrock Healthcare Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-MK-001

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Merck & Co

                            Deal Size : $1,866.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration with Merck to Develop Candidate CAR-NK Cell...

                            Details : The collaboration initially includes two CAR-NK programs (AB-MK-001 and AB-MK-002) with an option for a third, none of which are in Artiva’s current or planned pipeline.

                            Brand Name : AB-MK-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $30.0 million

                            January 28, 2021

                            Lead Product(s) : AB-MK-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Merck & Co

                            Deal Size : $1,866.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Anti-CD20 monoclonal antibody

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : 5AM Ventures

                            Deal Size : $78.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies

                            Details : The company plans to enter the clinic this year with AB-101 in combination with an anti-CD20 monoclonal antibody for the treatment of relapsed refractory B-cell lymphoma.

                            Brand Name : AB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 26, 2020

                            Lead Product(s) : AB-101,Anti-CD20 monoclonal antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : 5AM Ventures

                            Deal Size : $78.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth